Literature DB >> 14990346

Analysis of common IL-6 promoter SNP variants and the AnTn tract in humans and primates and effects on plasma IL-6 levels following coronary artery bypass graft surgery.

Daniel Kelberman1, Mark Fife, Matthew V Rockman, David J Brull, Patricia Woo, Steve E Humphries.   

Abstract

Interleukin-6 (IL-6) is a pro-inflammatory cytokine and major mediator of the acute phase response. Single nucleotide polymorphisms within the 5' flanking region (-597G>A, -572G>C and -174G>C) have previously been associated with increased risk of coronary heart disease and influencing transcription of IL-6 both in vitro and in vivo. In addition to these, a polymorphic AnTn tract is also present in the promoter of IL-6. Analysis in five different primate species demonstrated a G allele at -597, -572 and -174 in all species. By contrast, the AnTn tract was polymorphic in at least three species, and was roughly conserved in overall length despite an increase in the relative proportion of A versus T in the evolution of the human sequence from that in the ancestor of the great apes. The effect of the AnTn polymorphism on IL-6 levels was examined following coronary artery bypass graft surgery (CABG), a known inflammatory stimulus for IL-6 production. One hundred and thirty-two patients undergoing CABG were genotyped for the AnTn tract by automated sequencing. Four alleles were identified: A8T12 (allele frequency 0.35, 95% CI 0.29-0.40); A9T11 (0.26, 0.21-0.31); A10T11 (0.21, 0.16-0.26); and A10T10 (0.18, 0.14-0.23). Isolation of the effect of different alleles of the AnTn tract on an identical haplotypic background for the other polymorphisms in the promoter showed that individuals homozygous for A9T11 had significantly higher post-operative IL-6 levels than A10T11 homozygotes (275 +/- 46 pg/ml versus 152 +/- 29; P=0.04). The effect of the A8T12 allele could not be determined separately due to strong allelic association with -174C. The conserved length of the AnTn tract and the association in vivo with IL-6 levels strongly suggest the functionality of the tract on IL-6 expression, independent of contributions from other polymorphic sites within the promoter.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14990346     DOI: 10.1016/j.bbadis.2003.11.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

1.  C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older.

Authors:  Brandon L Pierce; Mary L Biggs; Marvalyn DeCambre; Alexander P Reiner; Christopher Li; Annette Fitzpatrick; Christopher S Carlson; Janet L Stanford; Melissa A Austin
Journal:  Cancer Causes Control       Date:  2009-03-08       Impact factor: 2.506

2.  Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer.

Authors:  Angela DeMichele; Robert Gray; Michelle Horn; Jinbo Chen; Richard Aplenc; William P Vaughan; Martin S Tallman
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

3.  Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis.

Authors:  Heiko Schotte; Hartmut Schmidt; Markus Gaubitz; Susanne Drynda; Jörn Kekow; Peter Willeke; Bernhard Schlüter
Journal:  Clin Rheumatol       Date:  2015-11-03       Impact factor: 2.980

4.  Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.

Authors:  Jun J Mao; H Irene Su; Rui Feng; Michelle L Donelson; Richard Aplenc; Timothy R Rebbeck; Frank Stanczyk; Angela DeMichele
Journal:  Breast Cancer Res       Date:  2011-01-20       Impact factor: 6.466

5.  IL-10, IL-6 and CD14 polymorphisms and sepsis outcome in ventilated very low birth weight infants.

Authors:  R John Baier; John Loggins; Krishna Yanamandra
Journal:  BMC Med       Date:  2006-04-12       Impact factor: 8.775

6.  Modifying effect of a common polymorphism in the interleukin-6 promoter on the relationship between long-term exposure to traffic-related particulate matter and heart rate variability.

Authors:  Martin Adam; Medea Imboden; Eva Boes; Emmanuel Schaffner; Nino Künzli; Harish Chandra Phuleria; Florian Kronenberg; Jean-Michel Gaspoz; David Carballo; Nicole Probst-Hensch
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

7.  Effects of systemic inflammation on relapse in early breast cancer.

Authors:  Nicholas P McAndrew; Lisa Bottalico; Clementina Mesaros; Ian A Blair; Patricia Y Tsao; Jennifer M Rosado; Tapan Ganguly; Sarah J Song; Phyllis A Gimotty; Jun J Mao; Angela DeMichele
Journal:  NPJ Breast Cancer       Date:  2021-01-22

8.  Interleukin-6 promoter polymorphism interacts with pain and life stress influencing depression phenotypes.

Authors:  David Kovacs; Nora Eszlari; Peter Petschner; Dorottya Pap; Szilvia Vas; Peter Kovacs; Xenia Gonda; Gyorgy Bagdy; Gabriella Juhasz
Journal:  J Neural Transm (Vienna)       Date:  2016-01-28       Impact factor: 3.575

9.  The IL6-174G/C Polymorphism Associated with High Levels of IL-6 Contributes to HCV Infection, but Is Not Related to HBV Infection, in the Amazon Region of Brazil.

Authors:  Maria Alice Freitas Queiroz; Angélica Menezes Santiago; Tuane Carolina Ferreira Moura; Ednelza da Silva Graça Amoras; Simone Regina Souza da Silva Conde; Izaura Maria Vieira Cayres-Vallinoto; Ricardo Ishak; Antonio Carlos Rosário Vallinoto
Journal:  Viruses       Date:  2022-02-28       Impact factor: 5.048

10.  Association of recipient and donor interleukin 6 polymorphisms 174 and 597 with outcome after allogeneic hematopoietic stem cell transplantation in children.

Authors:  Laura Wetzel; Susan Wittig; Bernd Gruhn
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-12       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.